CRIO & Sitero Partner To Drive Superior Enrollment, Speed, And Quality In Phase III Trial Using eSource

A detailed analysis of 140 research sites involved in a Phase III trial, conducted by Sitero and utilizing CRIO’s eSource platform, highlights significant advancements in trial performance and data quality. Sites leveraging the eSource platform demonstrated substantial improvements across key metrics. Additionally, these sites achieved a 5% higher patient retention rate compared to non-CRIO sites.

The study underscores the transformative potential of integrating technology at trial sites, with CRIO’s eSource platform enabling more efficient operations, robust compliance, and expedited timelines. These improvements translate into faster access to potentially life-saving treatments for patients. By embracing CRIO’s platform, pharmaceutical companies can streamline their trial processes, ensuring higher-quality outcomes while reducing delays.